louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01201460: DPBRN Blood Sugar Testing in Dental Patients
Official title: Blood Sugar Testing in Dental Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Hyperglycemia
Keywords: glucose testing
Lead sponsor: Dental Practice-Based Research Network
Sponsor class: NETWORK
Collaborators: name: National Institute of Dental and Craniofacial Research (NIDCR)
name: HealthPartners Institute
name: Kaiser Permanente
name: Permanente Dental Associates Group, Oregon
First posted: 2010-09-14
Enrollment: 498
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The human subjects direclty involved in this study were the patients who had sought dental treatment in the (DPBRN) practitioner-investigators' practices.

Brief summary: The principal goal of this study was to assess the feasibility of plasma glucose testing in private dental practice. A second aim was was to assess prevalence of plasma glucose abnormalities in dental patients seen by (DPBRN) practitioner-investigators.

Detailed description: The specific aims of this study were:

1. To quantify the percentage of (DPBRN) patients who meet the American Diabetes Association screening criteria and to describe the characteristics of these patients.
2. To quantify the acceptability of conducting glucose testing in the dental office and barriers to regular screening, as reported by (DPBRN) patients and practices.

Eligibility criteria: Inclusion Criteria:

* adults over the age of 19 who were scheduled for a visit with an exam

Exclusion Criteria:

* patients undergoing continuing treatment where an exam was not part of the visit were not eligible

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Gainesville
country: United States
facility: University of Florida College of Dentistry
state: Florida
city: Minneapolis
country: United States
facility: Health Partners Dental Group
state: Minnesota
city: Minneapolis
country: United States
facility: Health Partners Research Foundation
state: Minnesota
city: Portland
country: United States
facility: Kaiser Permanente Center for Health Research
state: Oregon
city: Portland
country: United States
facility: Permanente Denrtal Associates
state: Oregon
city: Copenhagen
country: Denmark
facility: University of Copenhagen Royal Dental College
Study officials:
affiliation: The University of Alabama at Birmingham
name: Andrei Barasch, DMD, MDSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05065060: Parkinson Progression Marker Initiative Online (PPMI Online)
Official title: Parkinson's Progression Markers Initiative Online Study (PPMI Online)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Parkinson Disease
Keywords: Parkinson
Neurodegenerative Disorder
Prodromal
At Risk
Participant Reported Outcomes
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research
Sponsor class: OTHER
First posted: 2021-10-01
Enrollment: 500000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.

Brief summary: Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.

PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Detailed description: PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical \[NCT04477785\], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation

Eligibility criteria: Inclusion Criteria:

* Parkinson Disease (PD) Participants:

  * Male or female age 18 years or older.
  * Has received a diagnosis of Parkinson's disease

Participants without PD:

* Male or female age 18 years or older.
* Has not received a diagnosis of Parkinson's disease

Primary outcomes:
measure: Unified Parkinson's Disease Rating Scale Ib & II
timeFrame: Baseline to 240 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Movement Disorders and Neuromodulation Center (MDNC)
state: California
Study officials:
affiliation: University of California, San Francisco
name: Caroline Tanner, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Institute for Neurodegenerative Disorders
name: Kenneth L Marek, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02715960: Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
Official title: Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Psoriasis Vulgaris
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2016-03-22
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases invalid(36.2%), 13 cases serious(9.4%). To investigate the influence of genetic factors on the curative effect and find the relationships between genetic variants and the response of Acitretin Capsules to treatment of Psoriasis Vulgaris.

Detailed description: Investigators analyzed the various levels of genetic factors, including: 1.To analysis the key gene variants which associated with ADME affect the efficacy of Acitretin Capsules; 2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy and side effects; 3. Direct sequencing of all exons in the gene in the patients of the response of serious and effectively, to explores the rare genetic variation may cause deterioration of treatment by Acitretin Capsules.

Eligibility criteria: Inclusion Criteria:

1. Diagnosed according to Classification criteria for Psoriasis vulgaris
2. Patients aged 18 to 70 years (to the date of screening)
3. PASI grade ≥7point
4. Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or Tretinoin cream, Phototherapy nearly one months before enrolled.
5. Total bilirubin \< 1.5 x ULN, AST(SGOT)/ALT(SGPT) \<2.5 x ULN if not liver metastases\<5 x ULN if known liver metastases, Creatinine clearance \<1.5 x ULN
6. Understanding the whole process of the study, voluntary participation and signed the informed consent

Exclusion Criteria:

1. Pregnant women, ready to pregnant or lactating women
2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history
3. Patients is liver function abnormal persons (ALT above the center laboratory normal limit) or hepatitis b patient grain carriers
4. Patients with chronic diarrhea, or peptic ulcer nearly 1 year
5. Patients suffering from malignant tumor
6. Patients suffering from acute and chronic infectious diseases
7. Mental disorders, history of alcohol abuse, drug or other substance abuse
8. Other cases which researchers believe that can not enroll

Primary outcomes:
measure: disease control rate
timeFrame: 8 weeks after the first treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Changsha
country: China
facility: Xiangya Hospital Central South University
state: Hunan
Study officials:
affiliation: Xiangya Hospital of Central South University
name: Xiang Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04429360: What is the Effect of Prolapse Surgery on Voiding?
Official title: What is the Effect of Prolapse Surgery on Voiding?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pelvic Organ Prolapse
Stress Urinary Incontinence
Overactive Bladder
Voiding Disorders
Urge Incontinence
Keywords: Pelvic Organ Prolapse
Surgery
3D/4D imaging
urinary incontinence
voiding dysfunction
patient reported outcome
Lead sponsor: Universiteit Antwerpen
Sponsor class: OTHER
First posted: 2020-06-12
Enrollment: 453
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women attending a gynecological unit with symptoms of pelvic organ prolapse and who will undergo pelvic floor surgery as management of their symptoms.

Brief summary: The aim of our study is to examine the effect of prolapse surgery on voiding. Our study is the very first one to combine several innovative low-invasive and low-cost methods to analyse the amelioration or deterioration of voiding function after surgery for pelvic organ prolapse using 3D/4D translabial ultrasound, home-uroflowmetry and patient reported quality of life outcomes.


Eligibility criteria: Inclusion Criteria:

* age ≥18 years
* Dutch, French or English- speaking women
* symptoms of pelvic organ prolapse
* preoperatively pelvic floor surgery.

Exclusion Criteria:

- history of neurological disease

Primary outcomes:
measure: Change in lower urinary tract symptoms pre- postoperatively
timeFrame: 1 year follow-up
measure: Change in lower urinary tract symptoms pre- postoperatively
timeFrame: 1 year follow-up
Secondary outcomes:
measure: Change in clinical outcome measures
timeFrame: 1 year follow-up
measure: Change in clinical outcome measures
timeFrame: 1 year follow-up
measure: Change in voiding
timeFrame: 1 year follow-up
measure: Change in QoL
timeFrame: 1 year follow-up
measure: Change in QoL
timeFrame: 1 year follow-up
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: University Hospital of Antwerp
state: Antwerp
Study officials:
References:
Clinical trial NCT01157260: The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
Official title: The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Kidney Failure, Chronic
Keywords: Indoxyl sulfate
AST-120
Lead sponsor: Ewha Womans University
Sponsor class: OTHER
First posted: 2010-07-07
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS.

IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.

Detailed description: The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients

Eligibility criteria: Inclusion Criteria:

* Patients with Chronic kidney disease (Stage3 - Stage4)
* Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information

Exclusion Criteria:

* Acute gastric or duodenal ulcer
* Severe constipation

Primary outcomes:
measure: Changes of FMD(Flow Mediated Dilatation)
timeFrame: 6 months
Secondary outcomes:
measure: Level of Indoxyl Sulfate
timeFrame: 3 months, 6 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Mokdong Hospital
Study officials:
affiliation: Ewha Womans University
name: Duk-Hee Kang, MD. PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00370760: Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Proliferative Vitreoretinopathy
Keywords: PVR
Oral colchicine
Dexamethasone
low molecular weight heparin
5-FU
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-09-01
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of oral colchicine combined with intraoperative infusion of dexamethasone, low molecular weight heparin and 5-FU during vitrectomy for management of established proliferative vitreoretinopathy (PVR)


Eligibility criteria: Inclusion Criteria:

* Cases with rhegmatogenous retinal detachment complicated by PVR grade C

Exclusion Criteria:

* History of pars plana vitrectomy for PVR grade C
* History of silicone oil injection
* History of ocular trauma
* Diabetic retinopathy
* Glaucoma
* Giant retinal tear

Primary outcomes:
measure: Retinal reattachment rate
Secondary outcomes:
measure: PVR recurrence,
measure: macular pucker,
measure: reoperation,
measure: ocular hypotony,
measure: visual acuity
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Hamid Ahmadieh, MD
Study officials:
affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
name: Hamid Ahmadieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04132076: Treatment Outcome After Ankle Joint Surgeries
Official title: Treatment Outcome After Ankle Joint Surgeries
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteochondral Lesion of Talus
Ankle Arthritis
Instability; Ankle (Ligaments) (Old Injury)
Impingement Syndrome of Ankle
Lead sponsor: University Medical Centre Ljubljana
Sponsor class: OTHER
First posted: 2019-10-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The invetigators will analyse cohort of patient after ankle joint surgery in the Department of Orthopaedic Surgery, UMC Ljubljana between 2008 and 2018.

Brief summary: Osteochondral lesion of talus (OLT), osteoarthrosis and impingement/instability syndrome are most common ankle joint pathologies. This study analyses outcome after various different operative treatment of aforementioned pathologies. Investigators hypothesis is that patient characteristics, type of lesion and surgical technique affect the result of treatment. The investigators will compare subjective (questionnaire) and objective (clinical examination) status of patient before and after operation.


Eligibility criteria: Inclusion Criteria:

* Patients with OLT treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
* Patients with ankle joint osteoarthritis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
* Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
* Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.

Exclusion Criteria:

* patient refuse to participate in study
* no respond of patient after invitation to answer a standardized questionnaire (EQ-5D, FAOS, Tegner activity score)
* no respond of patient after invitation to control examination after operation

Primary outcomes:
measure: FAOS questionnaire
timeFrame: 36 months after operation
measure: EQ-5D questionnaire
timeFrame: 36 months after operation
measure: Tegner activity score
timeFrame: 36 months after operation
Secondary outcomes:
measure: Kellgren and Lawrence score
timeFrame: 36 months after operation
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: Department of orthopaedic surgery, University medical centre Ljubljana
Study officials:
References:
citation: Kolar M, Brulc U, Strazar K, Drobnic M. Patient-reported joint status and quality of life in sports-related ankle disorders and osteoarthritis. Int Orthop. 2021 Apr;45(4):1049-1055. doi: 10.1007/s00264-020-04747-y. Epub 2020 Sep 17.
Clinical trial NCT02217176: Ultrasonography of the Neck: The Influence of Airway Devices on Vascular Topography in Pediatric Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ultrasonography, Pediatrics, Overlap, Vascular Structures
Lead sponsor: Ankara University
Sponsor class: OTHER
Collaborators: name: Harran University
First posted: 2014-08-15
Enrollment: 92
Sex: ALL
Minimum age (years): 1
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The pediatric population who were undergone any type of surgery under general anesthesia

Brief summary: Internal jugular venous catheterization is a challenging procedure in pediatric patients due to small size. Overlapping of the internal jugular vein (IJV) and common carotid artery (CCA) may jeopardize the success and increase the complication rate.However, the use of ultrasound as an assistance tool might be helpful to identify the relationship between the IJV and the CCA. Endotracheal intubation and insertion of laryngeal mask are the common options for the airway management during general anesthesia for central venous catheterization. In this observational study, the investigators aimed to investigate the impact of the laryngeal mask insertion or endotracheal intubation and the role of head rotation on the overlap of the IJV and CCA evaluated with ultrasound in pediatric patients undergoing any kind of surgical procedure.


Eligibility criteria: Inclusion Criteria:

* patients with American Society of Anesthesiologist status I-IV

Exclusion Criteria:

* patients with prior internal jugular vein catheterization or cardiovascular system anomaly

Primary outcomes:
measure: Primary outcome is the overlap percentages (%) of right and left IJVs before and just after insertion of LMA compared with ETT. Overlap percentage is calculated as overlap of IJV(mm)/carotid artery diameter(mm))*100 obtained from ultrasonographic images.
timeFrame: Obtaining ultrasonographic images takes 30 minutes on average per patient
Secondary outcomes:
measure: the relationship between IJV and CCA defined as anterior, anterolateral, lateral, anteromedial and medial according to the IJV's topographic location
timeFrame: Obtaining ultrasonographic images takes 30 minutes on average per patient
Other outcomes:
measure: the diameter of bilateral IJVs in mm
timeFrame: Obtaining ultrasonographic images takes 30 minutes on average per patient
Locations:
city: Ankara
country: Turkey
facility: Ankara University Department of Anesthesiology and Intensive Care Medicine
Study officials:
References:
Clinical trial NCT04722276: Fraction of Oxygen on Induction of Anesthesia in Infants
Official title: The Effect of Positive End-expiratory Pressure During Induction of General Anesthesia and Non-hypoxic Apnea Time in Infants: a Randomized Controlled Trials
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Apnea
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2021-01-25
Enrollment: 84
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Invesetigators evaluated the effect of positive end-expiratory pressure during anaesthesia induction on nonhypoxic apnoea time in infants. Invesetigators assigned infants to a 7 cmH2O positive end expiratory pressure (PEEP) with fraction of inspired oxygen 80% or 0 cmH2O PEEP with fraction of oxygen 80% group. Anaesthesia was induced with 0.02 mg kg atropine, 5 mg kg thiopental sodium and 3 to 5% sevoflurane, and neuromuscular blockade with 0.6 mg kg rocuronium. Thereafter, 80% oxygen was provided via face mask with volume-controlled ventilation of 6 ml kg tidal volume, and either 7 cmH2O or no positive end-expiratory pressure. After 3 min of ventilation, the infants' trachea was intubated but disconnected from the breathing circuit, and ventilation resumed when pulse oximetry reached 95%.


Eligibility criteria: Inclusion Criteria:

* We included paediatric patients aged 12 months or less about to receive general anaesthesia with endotracheal intubation.

Exclusion Criteria:

* Neonates, former preterm infants with gestational age less than 60 weeks at the day of surgery, with previous history of respiratory disease, those with anticipated difficult mask ventilation or intubation and those with upper respiratory infection within 3 weeks were excluded.

Primary outcomes:
measure: apnea time
timeFrame: during face mask ventilation, maximum 3 minutes.
Secondary outcomes:
measure: atelectasis score (0~72)
timeFrame: during anesthesia induction, maximum 5 minutes.
measure: Number of participants with gastric air insufflation
timeFrame: during anesthesia induction, maximum 5 minutes.
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hee-Soo Kim
state: Soul-t'ukpyolsi
Study officials:
References: